KOASTAL

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer's disease agitation, NMRA-898 in schizophrenia and NMRA-215 in car

Neumora Therapeutics' phase 3 KOASTAL-1 study of navacaprant in MDD fails to meet primary endpoint

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an efficacy signal in female participants; Company plans to fur

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an efficacy signal in female participants; Company plans to fur

Neumora Therapeutics Reports Data From KOASTAL-1 Study Of Navacaprant In Major Depressive Disorder. Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score co

--Neumora Therapeutics, Inc. a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced results from the Phase 3 KOASTAL-1 Study of navacaprant for the trea